Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum

Simply Wall St.06-08

AdvertisementWhy Pulse Biosciences is on investors’ radar Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641098671?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-06-08 12:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641098671","market":"us","top_or_hot":-1,"title":"Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Pulse Biosciences is on investors’ radar Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-strong-rece\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-08 12:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-strong-rece><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Pulse Biosciences is on investors’ radar Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-strong-rece\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLSE","symbol_name":"Pulse Biosciences, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-strong-rece","article_id":"2641098671","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-plse/pulse-biosciences/news/assessing-pulse-biosciences-plse-valuation-after-strong-rece","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641098671","pubTimestamp":1780893154,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Pulse Biosciences is on investors’ radar\nPulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 months that stand out against its recent trading history.\nSee our latest analysis for Pulse Biosciences.\nAgainst this backdrop, the recent 32.76% 30-day share price return and 30.23% 90-day share price return sit alongside an 89.17% year-to-date share price gain and a 3-year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLSE":"Pulse Biosciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"在近期股价强劲势头后评估Pulse Biosciences(PLSE)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":1.5},"content_text":"AdvertisementWhy Pulse Biosciences is on investors’ radar Pulse Biosciences (PLSE) has drawn fresh attention after a period of strong share price moves, including gains over the past month and past 3 months that stand out against its recent trading history. See our latest analysis for Pulse Biosciences. Against this backdrop, the recent 32.76% 30-day share price return and 30.23% 90-day share price return sit alongside an 89.17% year-to-date share price gain and a 3-year total shareholder return of 258.27%. Together, these figures point to strong momentum rather than a short-term spike. If you are looking beyond Pulse Biosciences for stocks with a similar high-growth angle in healthcare technology, it is worth scanning 39 healthcare AI stocks. With the stock up strongly this year and trading at $25.33 against an analyst price target of $30.67, the key question is simple: Is there still value on the table here, or is the market already pricing in future growth? Most Popular Narrative: 15.6% Undervalued Pulse Biosciences’ most followed narrative pegs fair value at $30.00, which sits above the last close at $25.33, and frames the recent share price strength in a longer term context.  A focused commercial model that targets key accounts in a few large metropolitan areas, along with positive reimbursement trends for Vybrance procedures, is aimed at driving higher account utilization and improving gross margins as disposables and full system sales scale relative to current GAAP net loss of US$19.4 million.  Read the complete narrative. Want to see what is behind this valuation gap? The narrative leans heavily on rapid revenue expansion, margin repair and a future earnings multiple that assumes strong adoption. The exact mix of those ingredients is where the story gets interesting. Result: Fair Value of $30.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the bullish story still hinges on very early Vybrance revenues against heavy quarterly losses and on multi year cardiac trials that could face delays or setbacks. Find out about the key risks to this Pulse Biosciences narrative. Another way to look at Pulse Biosciences’ value The bullish narrative leans on future earnings and growth assumptions, but the current P/B ratio of 26.4x versus 2.4x for the US Medical Equipment industry and 6.8x for peers points to a rich valuation. If sentiment cools, a shift toward those lower benchmarks could pressure the share price. See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:PLSE P/B Ratio as at Jun 2026Next Steps Mixed messages or a clear setup, either way this is a moment to move quickly, review the numbers yourself, and weigh up the 2 key rewards and 3 important warning signs. Looking for more investment ideas? If you stop with just one stock, you risk missing other opportunities that better fit your goals, risk comfort, and timeline across different sectors and styles.  Target potential mispricings by scanning companies that screen as high quality yet priced below their estimated worth using the 48 high quality undervalued stocks. Strengthen your income focus by checking stocks that combine robust yields with resilient business profiles through the 10 dividend fortresses. Prioritize resilience by reviewing companies with comparatively lower risk scores and steadier profiles using the 63 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641098671","isCrawlerRequest":true}